466 related articles for article (PubMed ID: 26276582)
1. Fasiglifam (TAK-875) Inhibits Hepatobiliary Transporters: A Possible Factor Contributing to Fasiglifam-Induced Liver Injury.
Li X; Zhong K; Guo Z; Zhong D; Chen X
Drug Metab Dispos; 2015 Nov; 43(11):1751-9. PubMed ID: 26276582
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes.
Hartman JC; Brouwer K; Mandagere A; Melvin L; Gorczynski R
Can J Physiol Pharmacol; 2010 Jun; 88(6):682-91. PubMed ID: 20628435
[TBL] [Abstract][Full Text] [Related]
3. Fasiglifam (TAK-875): Mechanistic Investigation and Retrospective Identification of Hazards for Drug Induced Liver Injury.
Otieno MA; Snoeys J; Lam W; Ghosh A; Player MR; Pocai A; Salter R; Simic D; Skaggs H; Singh B; Lim HK
Toxicol Sci; 2018 Jun; 163(2):374-384. PubMed ID: 28206647
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and sitaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytes.
Lepist EI; Gillies H; Smith W; Hao J; Hubert C; St Claire RL; Brouwer KR; Ray AS
PLoS One; 2014; 9(1):e87548. PubMed ID: 24498134
[TBL] [Abstract][Full Text] [Related]
5. Fasiglifam (TAK-875) Alters Bile Acid Homeostasis in Rats and Dogs: A Potential Cause of Drug Induced Liver Injury.
Wolenski FS; Zhu AZX; Johnson M; Yu S; Moriya Y; Ebihara T; Csizmadia V; Grieves J; Paton M; Liao M; Gemski C; Pan L; Vakilynejad M; Dragan YP; Chowdhury SK; Kirby PJ
Toxicol Sci; 2017 May; 157(1):50-61. PubMed ID: 28108665
[TBL] [Abstract][Full Text] [Related]
6. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans.
Yamashiro W; Maeda K; Hirouchi M; Adachi Y; Hu Z; Sugiyama Y
Drug Metab Dispos; 2006 Jul; 34(7):1247-54. PubMed ID: 16624871
[TBL] [Abstract][Full Text] [Related]
7. Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1)by bosentan: a mechanism for species differences in hepatotoxicity.
Leslie EM; Watkins PB; Kim RB; Brouwer KL
J Pharmacol Exp Ther; 2007 Jun; 321(3):1170-8. PubMed ID: 17374746
[TBL] [Abstract][Full Text] [Related]
8. Alpha-naphthylisothiocyanate modulates hepatobiliary transporters in sandwich-cultured rat hepatocytes.
Guo C; He L; Yao D; A J; Cao B; Ren J; Wang G; Pan G
Toxicol Lett; 2014 Jan; 224(1):93-100. PubMed ID: 24120425
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular organic anion-transporting polypeptides (OATPs) and multidrug resistance-associated protein 2 (MRP2) are inhibited by silibinin.
Wlcek K; Koller F; Ferenci P; Stieger B
Drug Metab Dispos; 2013 Aug; 41(8):1522-8. PubMed ID: 23695864
[TBL] [Abstract][Full Text] [Related]
10. Optimized Hepatocyte-Like Cells with Functional Drug Transporters Directly-Reprogrammed from Mouse Fibroblasts and their Potential in Drug Disposition and Toxicology.
Wu ZT; Yao D; Ji SY; Ni X; Gao YM; Hui LJ; Pan GY
Cell Physiol Biochem; 2016; 38(5):1815-30. PubMed ID: 27160211
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effect of fasiglifam on hepatitis B virus infections through suppression of the sodium taurocholate cotransporting polypeptide.
Nio Y; Akahori Y; Okamura H; Watashi K; Wakita T; Hijikata M
Biochem Biophys Res Commun; 2018 Jun; 501(3):820-825. PubMed ID: 29723527
[TBL] [Abstract][Full Text] [Related]
12. Identification of the transporters involved in the hepatobiliary transport and intestinal efflux of methyl 1-(3,4-dimethoxyphenyl)-3-(3-ethylvaleryl)-4-hydroxy-6,7,8-trimethoxy-2-naphthoate (S-8921) glucuronide, a pharmacologically active metabolite of S-8921.
Sakamoto S; Kusuhara H; Horie K; Takahashi K; Baba T; Ishizaki J; Sugiyama Y
Drug Metab Dispos; 2008 Aug; 36(8):1553-61. PubMed ID: 18474677
[TBL] [Abstract][Full Text] [Related]
13. The roles of MRP2, MRP3, OATP1B1, and OATP1B3 in conjugated hyperbilirubinemia.
Keppler D
Drug Metab Dispos; 2014 Apr; 42(4):561-5. PubMed ID: 24459177
[TBL] [Abstract][Full Text] [Related]
14. Estimation of transporters involved in the hepatobiliary transport of TA-0201CA using sandwich-cultured rat hepatocytes from normal and multidrug resistance-associated protein 2-deficient rats.
Fukuda H; Ohashi R; Ohashi N; Yabuuchi H; Tamai I
Drug Metab Dispos; 2010 Sep; 38(9):1505-13. PubMed ID: 20538722
[TBL] [Abstract][Full Text] [Related]
15. In vitro investigation of the hepatobiliary disposition mechanisms of the antifungal agent micafungin in humans and rats.
Yanni SB; Augustijns PF; Benjamin DK; Brouwer KL; Thakker DR; Annaert PP
Drug Metab Dispos; 2010 Oct; 38(10):1848-56. PubMed ID: 20606004
[TBL] [Abstract][Full Text] [Related]
16. Determination of OATP-, NTCP- and OCT-mediated substrate uptake activities in individual and pooled batches of cryopreserved human hepatocytes.
De Bruyn T; Ye ZW; Peeters A; Sahi J; Baes M; Augustijns PF; Annaert PP
Eur J Pharm Sci; 2011 Jul; 43(4):297-307. PubMed ID: 21605667
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of bile acid transport across Na+/taurocholate cotransporting polypeptide (SLC10A1) and bile salt export pump (ABCB 11)-coexpressing LLC-PK1 cells by cholestasis-inducing drugs.
Mita S; Suzuki H; Akita H; Hayashi H; Onuki R; Hofmann AF; Sugiyama Y
Drug Metab Dispos; 2006 Sep; 34(9):1575-81. PubMed ID: 16760228
[TBL] [Abstract][Full Text] [Related]
18. Interaction of digitalis-like compounds with liver uptake transporters NTCP, OATP1B1, and OATP1B3.
Gozalpour E; Greupink R; Wortelboer HM; Bilos A; Schreurs M; Russel FG; Koenderink JB
Mol Pharm; 2014 Jun; 11(6):1844-55. PubMed ID: 24754247
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Hepatobiliary Transport Activity by the Antibacterial Agent Fusidic Acid: Insights into Factors Contributing to Conjugated Hyperbilirubinemia/Cholestasis.
Lapham K; Novak J; Marroquin LD; Swiss R; Qin S; Strock CJ; Scialis R; Aleo MD; Schroeter T; Eng H; Rodrigues AD; Kalgutkar AS
Chem Res Toxicol; 2016 Oct; 29(10):1778-1788. PubMed ID: 27676153
[TBL] [Abstract][Full Text] [Related]
20. Expression and transport function of drug uptake transporters in differentiated HepaRG cells.
Kotani N; Maeda K; Debori Y; Camus S; Li R; Chesne C; Sugiyama Y
Mol Pharm; 2012 Dec; 9(12):3434-41. PubMed ID: 22897388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
